Simple, home-use, neurostimulation treatment for parkinson's disease dementia (sharpen)
Ended Project Grant Awarded Last action
- Award ID
- R43NS132653
- Recipient
-
Scion Neurostim, Inc. UEI H9R1VL1K6KB3
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,034,531
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Parkinson's disease dementia (PDD) is a frequent non-motor symptom in patients with parkinson's disease (PD). PDD is associated with cognitive decline that can increase morbidity and mortality and dramatically reduce patient quality of life. Three out of four PD patients will develop PDD, yet the only FDA-approved treatment for PDD is rivastigmine which provides effects that are short-lived and modest at best and may worsen PD motor symptoms. Furthermore, gold standard therapies for parkinsonian motor impairments (i.e., levodopa and deep brain stimulation) can worsen PDD, yet stopping treatment is typically not recommended. To address this dire need, scion neurostim, INC has developed a novel, home-use device that non-invasively stimulates nuclei in the brainstem that send projections throughout the brain to regulate a variety of functions including cognition, memory, well-being, and mood. In a previous double-blind, randomized controlled trial, eight weeks of device treatments dramatically improved both motor and non-motor symptoms in PD patients. Device treatments were well tolerated and safe with only infrequent, transient, and mild side effects. Importantly, a sub-analysis of data from participants with evidence of either mild cognitive impairment or dementia revealed that device treatment was associated with significantly improved cognitive performance according to the montreal cognitive assessment. Treatment adherence was excellent and study participants remained blind to their treatment allocation. Furthermore, the kinetics of the clinical responses indicate that longer treatment periods are likely to result in even greater clinical improvements. Thus, in this project, scion will conduct a single-arm clinical trial to evaluate the safety and feasibility of non-invasive brainstem stimulation with scion's device over a period of 12 weeks in PDD patients. Further, IT will explore the potential for scion's device to treat cognitive and other motor and non-motor symptoms associated with PDD, which, if favorable, will enable the design and powering of a pivotal trial.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$287,473 | |
| Amendment | $0 | |
| Amendment | $327,682 | |
| Amendment | $327,682 | |
| Original award | $666,640 |
Quick answers
Who received award R43NS132653?
R43NS132653 was awarded to Scion Neurostim, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on July 15, 2023.
How much is award R43NS132653 worth?
$1,034,531 has been obligated on R43NS132653.
Which agency awarded R43NS132653?
National Institute of Neurological Disorders and Stroke (National Institutes of Health) awarded R43NS132653, with funding from National Institute on Aging (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award